Long non‑coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients

  • Authors:
    • Chaofeng Ding
    • Zhe Yang
    • Zhen Lv
    • Chengli Du
    • Heng Xiao
    • Chuanhui Peng
    • Shaobing Cheng
    • Haiyang Xie
    • Lin Zhou
    • Jian Wu
    • Shusen Zheng
  • View Affiliations

  • Published online on: November 24, 2014     https://doi.org/10.3892/ol.2014.2730
  • Pages: 955-963
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

PVT1, which maps to chromosome 8q24, is a copy number amplification‑associated long non‑coding RNA. Overexpression of PVT1 is a powerful predictor of tumor progression and patient survival in a diverse range of cancer types. However, the association between PVT1 and hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to examine the expression pattern of PVT1, and its clinical significance in HCC. Between 2003 and 2012, reverse transcription‑quantitative polymerase chain reaction was used to determine the expression levels of PVT1 in two independent cohorts: Cohort one, 58 HCC resection samples; and cohort 2, 214 HCC transplant samples. Additionally, the correlation between PVT1 expression levels and clinical parameters and outcomes was analyzed. The relative expression levels of PVT1 were significantly higher in cancerous tissues compared with the corresponding non‑cancerous tissues (cohort one, P=0.0016; cohort two, P=0.0274). Furthermore, overexpression of PVT1 was associated with a higher serum α‑fetoprotein expression level (P=0.011) and a higher recurrence rate (P=0.004). Kaplan‑Meier analysis indicated that the patients with high PVT1 expression exhibited poor recurrence‑free survival (P=0.021), and multivariate analysis demonstrated that high levels of PVT1 expression are an independent predictor for HCC recurrence (P=0.042; hazard ratio, 1.653). Thus, the high expression levels of PVT1 in HCC may serve as a novel biomarker for predicting tumor recurrence in HCC patients, and as a potential therapeutic target.
View Figures
View References

Related Articles

Journal Cover

February 2015
Volume 9 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Ding, C., Yang, Z., Lv, Z., Du, C., Xiao, H., Peng, C. ... Zheng, S. (2015). Long non‑coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncology Letters, 9, 955-963. https://doi.org/10.3892/ol.2014.2730
MLA
Ding, C., Yang, Z., Lv, Z., Du, C., Xiao, H., Peng, C., Cheng, S., Xie, H., Zhou, L., Wu, J., Zheng, S."Long non‑coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients". Oncology Letters 9.2 (2015): 955-963.
Chicago
Ding, C., Yang, Z., Lv, Z., Du, C., Xiao, H., Peng, C., Cheng, S., Xie, H., Zhou, L., Wu, J., Zheng, S."Long non‑coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients". Oncology Letters 9, no. 2 (2015): 955-963. https://doi.org/10.3892/ol.2014.2730